The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Topic: Lipids - Primary Care

Wednesday, 21 February 2018
In the first 15 months of its operation, Bradford’s Healthy Hearts campaign has significantly improved the cardiovascular health of local people, and saved an estimated £1.2 m for the clinical commissioning group. 
Category: Editorial
Wednesday, 21 February 2018
Raised blood cholesterol is a major risk factor in developing coronary heart disease and other cardiovascular diseases. Effective and well-tolerated lipid-lowering treatment improves outcomes for patients with elevated cholesterol, especially those with familial hypercholesterolaemia.
Category: Editorial
Tuesday, 11 April 2017
Detailed results from the FOURIER cardiovascular outcomes trial on evolocumab were presented at a late-breaking oral presentation at the American College of Cardiology meeting in Washington DC recently. This is the first major outcomes study to be published for a PCSK9 inhibitor – a new class of cholesterol-lowering medicines.
Tuesday, 03 October 2017
People who complain of myalgia caused by statins may be suffering from a genetic problem, according to a recent paper published in the European Heart Journal.
Wednesday, 06 December 2017
A study suggests that high-risk patients are being under-prescribed statins whereas patients in low-risk categories are being overtreated. Researchers have shown that statins are usually prescribed without recording of the QRISK2 cardiovascular risk assessment score recommended by NICE. Even when a score is documented, the majority of high-risk patients do not receive statins
Wednesday, 06 December 2017
Data analysis of patients’ prescriptions dispensed at a regional chain of community pharmacies found that 40% of patients who are prescribed statins never return for a second prescription.
Category: Have You Heard
Tuesday, 27 February 2018
A recent study using data from the UK Paediatric Familial Hypercholesterolaemia Register shows that statin therapy reduces LDL cholesterol by 31% with no associated liver or muscle damage. Statin use in children is not associated with any reductions in growth rate and is safe in childhood, with no biochemical evidence of toxicity over a 2- to 3-year period.
Tuesday, 30 May 2017
Muscle-related symptoms are less commonly reported when patients and their doctors are unaware that statin therapy is being used, compared to when they are aware, according to a new study on ASCOT-LLA trial data.

Article search and filter